Navigation Links
Advanced Cardiac Therapeutics Completes $5 Million Financing
Date:1/11/2010

LAGUNA BEACH, California, January 11 /PRNewswire/ -- Advanced Cardiac Therapeutics, Inc. ("ACT"), a developer of advanced irrigated cardiac ablation systems, announced today that it has completed a $5 million 'Series B' equity financing. The financing was led by NBGI Ventures, a venture capital firm specialized in medical technology investments, and is expected to fund commercialisation in Europe.

ACT was founded in 2007 to develop a novel irrigated radiofrequency cardiac ablation catheter with a diagnostic application of established microwave radiometry technology in association with the founder of the technology, Dr Kenneth Carr, and an experienced catheter development partner, Contract Medical International, based in Dresden, Germany.

Cardiac catheter ablation procedures are used to treat a variety of cardiac arrhythmias including Atrial Fibrillation (AF), which is estimated to affect over five million people in the USA and Europe. The procedures involve advancing a catheter into the heart and selectively ablating certain areas of tissue in order to prevent the spread of electrical signals that give rise to the arrhythmia. Most catheter ablation procedures are now conducted with irrigated catheters, in which saline is pumped through the tip during the application of energy, in order to prevent the tip from overheating and increasing risk of blood clotting events. However, as the tip is cooled, it is not possible to estimate the effect of the energy on the tissue by measuring the temperature at the surface of the tissue. ACT's technology will enable for the first time measurement of tissue temperature with an irrigated catheter. This will permit Electro-Physiologists greater control in their lesion creation and has the potential to improve patient outcomes.

"Unlike any other catheter today, ACT's technology allows the Electro-Physiologist to optimize irrigated catheter generated lesions by knowing the real time ablation temperature inside the cardiac tissue", Peter van der Sluis, ACT's CEO, commented. "The completion of our B round funding allows us to fully prepare for the commercial launch of ACT's technology in 2010."

Gerard Harper of NBGI Ventures added: "We are delighted to support this exciting opportunity within the rapidly-growing cardiac catheter ablation market. ACT's system has potential to bring a step-change in lesion control during these procedures and improve outcomes for patients."

About Advanced Cardiac Therapeutics

Headquartered in Laguna Beach, California, USA, ACT specializes in advanced irrigated cardiac catheter ablation systems with proprietary temperature-sensing technology based on microwave radiometry.

About NBGI Ventures (http://www.nbgiventures.com)

NBGI Ventures, established in 2001, manages funds with over EUR100 million in total commitments and focuses on leading investments in innovative medical technology companies. NBGI Ventures is based in London and considers investments across Europe and the US. Companies it has supported to date include Advanced Cardiac Therapeutics (USA), Biospace Med (France), BoneSupport (Sweden), Estech (USA), Forth Photonics (UK), Quanta Fluid Solutions (UK), Reverse Medical (USA), SuperSonic Imagine (France), 2010 Perfect Vision (Germany) and Upfront Chromatography (Denmark). NBGI Ventures is a division of NBGI Private Equity Limited, which is authorised and regulated by the Financial Services Authority.

    For more information contact:

    Advanced Cardiac Therapeutics
    Peter van der Sluis, CEO
    T: +1-949-500-0192
    E: pvandersluis@actmed.net

    Media enquiries:
    Hogarth
    Julian Walker / Sarah MacLeod
    T: +44(0)20-7357-9477


SOURCE Advanced Cardiac Therapeutics


'/>"/>
SOURCE Advanced Cardiac Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avazzia and ChiroCode Institute Jointly Market Advanced Technology for Relief of Chronic Pain
2. Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World
3. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
4. Advanced Life Sciences Restanza Shows 100% Survival in Tularemia Pivotal Animal Study
5. Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments
6. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
7. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
8. GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
9. Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
(Date:1/19/2017)... -- Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, ...   Major research investment to work ...   The Milner Therapeutics Institute today announces ... partner to the Milner Therapeutics Consortium. Pfizer has agreed ... of materials between industry and academia and allocation of ...
(Date:1/19/2017)... 2017 While various reports ... reducing the FDA,s regulatory strictness as a way ... drug industry, many of the leading biotech and ... and development of advanced drug treatments and therapies.  ... developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... International Protein, a company based out of Australia that focuses ... January ECRM trade show in Hilton Head, SC. , International Protein was founded ... a line of products that would elevate her fitness regime. At this ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... sugar-free alternative VW+ 002. The drinks have been produced in collaboration with Zlatan ... perform during your workout. , After a successful launch in Sweden last year, ...
(Date:1/20/2017)... ... 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went ... creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age ... at 19 years of age, he joined the Navy and got married right out of ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children and adults ... and achievable answer. “The Land of More and More” is the creation of published ... Indiana where he works with the children’s ministry department. , Michael says that ...
Breaking Medicine News(10 mins):